When viewed alongside HFpEF trials such as SUMMIT and STEP‐HFpEF, the emerging picture is that dual incretin agonism can simultaneously improve HF‐related symptoms and haemodynamics in obesity‐related HFpEF while lowering long‐term atherosclerotic event risk without an apparent trade‐off in cardiovascular safety. This evidence concerns the gene GCG and Obesity.